Chapter 4. Stimulation of Toll-Like Receptor 9 for Enhancing Vaccination

  1. Rimas Orentas PhD3,
  2. James W. Hodge PhD4 and
  3. Bryon D. Johnson PhD5
  1. Daniel E. Speiser MD1 and
  2. Arthur M. Krieg MD2

Published Online: 1 MAR 2007

DOI: 10.1002/9780470170113.ch4

Cancer Vaccines and Tumor Immunity

Cancer Vaccines and Tumor Immunity

How to Cite

Speiser, D. E. and Krieg, A. M. (2008) Stimulation of Toll-Like Receptor 9 for Enhancing Vaccination, in Cancer Vaccines and Tumor Immunity (eds R. Orentas, J. W. Hodge and B. D. Johnson), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470170113.ch4

Editor Information

  1. 3

    Departments of Pediatrics, Medicine, Microbiology and Molecular Genetics, Medical College of Wisconsin and the Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI, USA

  2. 4

    Department of Medical Biology, University of Tennessee Medical Center and Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

  3. 5

    Department of Pediatrics, Medical College of Wisconsin and the Children's Research Institute, Children's Hospital of Wisconsin., Milwaukee, WI, USA

Author Information

  1. 1

    Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital of Lausanne, Switzerland

  2. 2

    Department of Internal Medicine, The University of Iowa, Iowa City, IA, and Coley Pharmaceutical Group, Wellesley, MA, USA

Publication History

  1. Published Online: 1 MAR 2007
  2. Published Print: 22 JAN 2008

ISBN Information

Print ISBN: 9780470074749

Online ISBN: 9780470170113

SEARCH

Keywords:

  • toll-like receptors (TLRs) and innate immune responses;
  • CpG ODN adjuvants and infectious disease vaccines;
  • TLR9 activation with CpG ODN

Summary

This chapter contains sections titled:

  • Introduction

  • The Role of TLR9 as Receptor for CpG ODN

  • Identification of Distinct Classes of Immune Stimulatory CpG ODN

  • CpG ODN Mechanisms Action in Stimulating Innate and Adaptive Immunity

  • CpG ODN as Adjuvants for Infectious Disease Vaccines

  • CpG ODN Synergy with other Adjuvants

  • Human Clinical Trials with CpG ODN to Adjuvant Infectious Disease Vaccines

  • Efficacy of CpG ODN as Vaccine Adjuvants in Mouse Tumor Models

  • Human Clinical Trials of CpG ODN Adjuvants for Cancer Vaccines

  • Safety of CpG ODN as Vaccine Adjuvant

  • Conclusions

  • References